{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:50:08Z","timestamp":1718949008821},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,3,7]]},"DOI":"10.18632\/oncotarget.15180","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T17:56:15Z","timestamp":1486576575000},"page":"16259-16274","source":"Crossref","is-referenced-by-count":7,"title":["Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Prexy","family":"Modi","sequence":"first","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumudha","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"issue":"7","key":"1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma","volume":"21","author":"Gandhi","year":"2015","journal-title":"Clinical cancer research"},{"issue":"22","key":"2","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"2","key":"3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Giese","year":"2011","journal-title":"Blood"},{"issue":"13","key":"4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Burger","year":"2011","journal-title":"Blood"},{"issue":"12","key":"5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Johnson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"6","doi-asserted-by":"crossref","first-page":"e83830","DOI":"10.1371\/journal.pone.0083830","article-title":"The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells","volume":"8","author":"Burger","year":"2013","journal-title":"PloS one"},{"issue":"11","key":"7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Ervin","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"7","key":"8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Hsieh","year":"2015","journal-title":"Clinical cancer research"},{"issue":"25","key":"9","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"Coutre","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Kipps","year":"2016","journal-title":"Blood"},{"issue":"10","key":"11","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Zelenetz","year":"2015","journal-title":"Leukemia & lymphoma"},{"issue":"24","key":"12","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","article-title":"Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block","volume":"15","author":"Burger","year":"2009","journal-title":"Clinical cancer research"},{"issue":"4","key":"13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update","volume":"57","author":"Zinzani","year":"2016","journal-title":"Leukemia & lymphoma"},{"issue":"24","key":"14","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood-2013-12-541433","article-title":"Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"issue":"5","key":"15","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.18632\/oncotarget.6685","article-title":"CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia","volume":"7","author":"Lopez-Guillermo","year":"2016","journal-title":"Oncotarget"},{"issue":"21","key":"16","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Colomer","year":"2008","journal-title":"Clinical cancer research"},{"issue":"4","key":"17","first-page":"568","article-title":"GammaH2AX and its role in DNA double-strand break repair","volume":"84","author":"Krogan","year":"2006","journal-title":"Biochem Cell Biol"},{"issue":"12","key":"18","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","article-title":"Oncogenic PI3K deregulates transcription and translation","volume":"5","author":"Vogt","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"19","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s10637-013-0002-4","article-title":"Bcl-2 antagonists: a proof of concept for CLL therapy","volume":"31","author":"Gandhi","year":"2013","journal-title":"Invest New Drugs"},{"issue":"1","key":"20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Niemeyer","year":"2008","journal-title":"Clinical cancer research"},{"issue":"4 Suppl 13","key":"21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Seminars in oncology"},{"issue":"26","key":"22","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Huguet","year":"2009","journal-title":"Journal of clinical oncology"},{"issue":"5828","key":"23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Elledge","year":"2007","journal-title":"Science"},{"issue":"3","key":"24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Shiloh","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6967","key":"25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1","volume":"426","author":"Korsmeyer","year":"2003","journal-title":"Nature"},{"issue":"9","key":"26","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Fegan","year":"2008","journal-title":"Blood"},{"issue":"14","key":"27","first-page":"2843","article-title":"MCL-1 localizes to sites of DNA damage and regulates DNA damage response","volume":"9","author":"Duronio","year":"2010","journal-title":"Cell cycle"},{"issue":"9","key":"28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.onc.1200927","article-title":"Induction of BCL2 family member MCL1 as an early response to DNA damage","volume":"14","author":"Craig","year":"1997","journal-title":"Oncogene"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R","article-title":"MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation","volume":"166","author":"Craig","year":"1996","journal-title":"J Cell Physiol"},{"issue":"8","key":"30","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Craig","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"31","doi-asserted-by":"crossref","first-page":"39458","DOI":"10.1074\/jbc.M006626200","article-title":"Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen","volume":"275","author":"Yeh","year":"2000","journal-title":"J Biol Chem"},{"issue":"8","key":"32","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1091\/mbc.e07-11-1171","article-title":"An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation","volume":"19","author":"Duronio","year":"2008","journal-title":"Mol Biol Cell"},{"issue":"Pt 3","key":"33","first-page":"659","article-title":"A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1","volume":"387","author":"Duronio","year":"2005","journal-title":"The Biochemical journal"},{"issue":"11","key":"34","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/cdd.2010.56","article-title":"ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response","volume":"17","author":"Porteu","year":"2010","journal-title":"Cell death and differentiation"},{"issue":"3","key":"35","first-page":"e00535","article-title":"MCL-1 depletion impairs DNA DSB repair and re-initiation of stalled DNA replication forks","volume":"37","author":"Pandita","year":"2017","journal-title":"Molecular and cellular biology"},{"issue":"21","key":"36","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1128\/MCB.05737-11","article-title":"BID binds to replication protein A and stimulates ATR function following replicative stress","volume":"31","author":"Zinkel","year":"2011","journal-title":"Molecular and cellular biology"},{"issue":"4","key":"37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.molcel.2007.12.029","article-title":"Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway","volume":"29","author":"Deng","year":"2008","journal-title":"Molecular cell"},{"issue":"2","key":"38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/nar\/gku1358","article-title":"Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation","volume":"43","author":"Deng","year":"2015","journal-title":"Nucleic acids research"},{"issue":"31","key":"39","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"23","author":"Craig","year":"2004","journal-title":"Oncogene"},{"issue":"9","key":"40","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2008-07-170241","article-title":"Mcl-1: the 1 in CLL","volume":"112","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"6","key":"41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Green","year":"2006","journal-title":"Molecular cell"},{"issue":"14","key":"42","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Edwards","year":"2010","journal-title":"FEBS letters"},{"issue":"6","key":"43","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Byrd","year":"2012","journal-title":"Blood"},{"issue":"5","key":"44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/ni.2016","article-title":"STIM1, PKC-delta and RasGRP set a threshold for proapoptotic Erk signaling during B cell development","volume":"12","author":"Weiss","year":"2011","journal-title":"Nature immunology"},{"issue":"9","key":"45","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Gandhi","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/leu.2011.364","article-title":"Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells","volume":"26","author":"Colomer","year":"2012","journal-title":"Leukemia"},{"issue":"16","key":"47","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia","volume":"21","author":"Gandhi","year":"2015","journal-title":"Clinical cancer research"},{"issue":"26","key":"48","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Elter","year":"2011","journal-title":"Journal of clinical oncology"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12054","article-title":"A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL","author":"Wierda","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Loscertales","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"23","key":"51","first-page":"LBA","article-title":"Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study","volume":"126","author":"Hillmen","year":"2015","journal-title":"Blood"},{"key":"52","first-page":"17","article-title":"Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL","author":"Starr","year":"2016","journal-title":"American health & drug benefits"},{"issue":"6","key":"53","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","article-title":"Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma","volume":"66","author":"Kahl","year":"2010","journal-title":"Cancer chemotherapy and pharmacology"},{"issue":"11","key":"54","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","article-title":"A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours","volume":"96","author":"Vermorken","year":"2007","journal-title":"British journal of cancer"},{"issue":"9","key":"55","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1349-7006.2010.01633.x","article-title":"Japanese Bendamustine Lymphoma Study G. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"101","author":"Tobinai","year":"2010","journal-title":"Cancer science"},{"issue":"12","key":"56","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neo.2014.10.002","article-title":"Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia","volume":"16","author":"Gandhi","year":"2014","journal-title":"Neoplasia"},{"issue":"2","key":"57","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:59:37Z","timestamp":1589129977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3,7]]}},"alternative-id":["15180","28187444"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15180","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]}}}